The Effect of Bromocriptine on the Liver of Immature Female Rats by Al-Hamdani, Nada M. H. et al.
  
Biological Research                                  ISSN(Online): 2517-9586   
 
30 
                                                             PSM Biological Research | https://journals.psmpublishers.org/index.php/biolres 
Research Article                                      2020 │Volume 5│Issue 1│30-39 
Article Info 
 
 Open Access 
 
Citation: Al-Hamdani, N.M.H., Ali, 
A.M.H., Al-Khatib, B.Y.H., Al-
Shaibani, E.S., 2020. The Effect 
of Bromocriptine on the Liver of 
Immature Female Rats. PSM Biol. 
Res., 5(1): 30-39. 
 
 
Received: November 30, 2019 
 
Accepted: January 20, 2020 
 
Online first: January 24, 2020 
 
Published: January 31, 2020 
 
 
*
Corresponding Author:  
Nada M. H. Al-Hamdani 
 
Email: 
hamdaninadam@gmail.com 
 
 
Copyright: ©2020 PSM. This work 
is an open-access article 
distributed under the terms of the 
Creative Commons Attribution-
Non Commercial 4.0 International 
License. 
 
 
 
 
 
Scan QR code to see this 
publication on your mobile device. 
 
 
 
 The Effect of Bromocriptine on the Liver of 
Immature Female Rats 
 
Nada M. H. Al-Hamdani
1*
, Ameen M. H. Ali
2
, Bushra Y. H. Al-Khatib
1
, 
Elham Shukri Al-Shaibani
1
 
 
1
Department of Zoology, Faculty of Science, Sana’a University, Yemen.           
2
The Committee of Research and Strategy Studies, Yemen. 
 
Abstract: 
The present study was performed to determine the effect of bromocriptine 
(BRO) a dopamine agonist on the liver of immature female rats. Sixty-five 
immature rats (15 days old) weighing 20-25g were assigned into four groups (20 
for each group except the first group of 5 animals), the first group was initial 
control sacrificed on day 1 of the experiment. The second group served as 
control and received vehicle (IP), the third and fourth group received BRO (IP) at 
2.5 and 5 mg/kg BW respectively for two durations (7 days and 21 days). Five 
animals of each group were maintained for 1 month without treatment for 
recovery study. BRO treatment caused; i) a significant decrease in the body 
weight, ii) a significant increase in the weight of the liver, iii) a significant 
increase in serum levels of alkaline phosphatase in immature rats of both 
treated groups when compared to the control group. Histological changes in the 
liver were observed in both BRO treated groups of each duration indicating that 
BRO induced liver injury. From the present study, we conclude that despite the 
effect of BRO in the liver of immature female rats, a period of one month without 
treatment was sufficient for the recovery of BRO effects. 
Keywords: Bromocriptine, immature rats, liver, Recovery. 
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INTRODUCTION 
Bromocriptine, an ergot alkaloid 
derivative, structurally related to dopamine and 
suggested to be a dopamine D2 receptor agonist 
(Barbieri and Ryan, 1983). BRO is widely used 
clinically for the treatment of patients with 
microprolactinoma and macroprolactinoma. With 
this drug treatment, serum prolactin 
concentration usually dropped to the normal 
range and directly binds to pituitary dopamine 
D2 receptors and inhibits prolactin secretion 
through the inhibition of adenyl cyclase activity 
(Barbieri and Ryan, 1983). BRO directly 
activates lactotrope dopamine receptors, leading 
to the inhibition of spontaneous and TRH-
induced release of prolactin (Schwartz, 2004).  
BRO is effective as long as its administration is 
continued (Thorner et al., 1980).  BRO has side 
effects with the doses required for prolactin 
suppression viz. nausea, vomiting, and postural 
hypotension with dizziness, drowsiness, fatigue, 
headache, indigestion, light-headedness, loss of 
appetite, nausea, stuffy or runny nose, 
weakness, etc., but these symptoms usually 
disappear within two to three days (Lancranjan, 
1981). It has been reported that BRO is also a 
common drug for the therapy of Parkinson’s 
disease (Ahlskog, 1994; Ogawa, 1998). 
Previous reports showed that BRO exerts 
pharmacological effects on the nervous system 
as it decreases the spontaneous firing rate of 
neurons in the cortex and the pars compacta of 
the substantia nigra (Bioulac et al., 1978) and 
inhibited the tuberoinfundibular dopaminergic 
neuron activity (Demarest et al., 1985). The 
side-effects of BRO on the cardiovascular 
system have also been investigated. Treatment 
with BRO decreases blood pressure and heart 
rate in both experimental animals and in humans 
(Hof and Hof 1984; Ageel et al., 1987; 
Roquebert et al., 1991; Schobel et al., 1995).  
Meanwhile, the results of numerous studies 
indicated that BRO affects adrenal function in 
pigs (Klemcke et al., 1990). Moreover, it has 
been reported that BRO treatment in immature 
female rats delayed the onset of puberty and 
interfered with the follicular development and the 
ovarian activity which was evidenced by the 
reduction in the number of healthy follicles and 
increase in the number of atretic follicles (Ameen 
et al., 2011). 
Many studies reported that the usage of 
drugs has an adverse effect or a harmful and 
undesired effect on the body. Adverse effects 
may cause a reversible or irreversible change, 
including an increase or decrease in the 
susceptibility of the individual to other chemicals, 
foods or procedures, such as drug interactions 
(Green and Spencer, 1966). Drugs are important 
causes of liver injury, more than 900 drugs, 
toxins, and herbs have been reported to cause 
liver injury, and drugs account for 20-40% of all 
instances of fulminant hepatic failure (Mehta et 
al., 2014). It has been reported that BRO 
induced acute hepatitis in Parkinson's disease 
patients (Liberato et al., 1992) and hepatotoxicity 
and nephrotoxicity in mice (Adejoke et al., 2014). 
Besides, a recent study categorized 
bromocriptine as a drug-induced liver injury 
(Bjornsson and Hoofnagle, 2016). Toxic effects 
on the kidneys related to medications are both 
common and expected. Any drugs have 
nephrotoxic potential and some of them can 
cause more than one pattern of injury (Zager, 
1997).  
 There are no studies on the effects of 
BRO on the gross and histomorphology of the 
liver in immature female rats to date. Data on the 
effects of BRO on the liver function test viz. 
analysis of alkaline phosphatase is limited. 
Further, the reversible effect of BRO is not 
studied so far. Therefore, it is necessary to know 
the reversibility effects of BRO by the cessation 
of treatment. Hence, the study aimed at finding 
out; whether the administration of two different 
doses (2.5 and 5 mg/kg BW) of BRO for two 
durations (7 and 21 days) have any toxic effects 
on the liver in immature female rats? Whether or 
not the effects of BRO are reversible?  
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MATERIALS AND METHODS 
Chemicals 
Technical grade bromocriptine was kindly 
purchased from Sigma-Aldrich, St. Louis, USA. 
Ethical approval 
The protocols were approved by the 
Institutional animal ethics committee and the 
guidelines of CPCSEA, Govt. of India were 
followed for care and maintenance of animals.   
Animals and treatment 
 Sixty-five immature female Wistar albino 
rats (15 days old) weighing 20-25g, originally 
obtained from an inbred population of Central 
Animal Facility, Department of Zoology, 
University of Mysore, India.  The animals were 
housed in polypropylene cages (5 animals per 
cage) with husk as the bedding material and 
kept under natural photo thermal conditions. The 
animals were supplied with dry food pellets and 
water ad libitum during the period of the 
experiment. Bodyweight of each mouse was 
recorded before the commencement of the 
treatment (initial BW). Animals were divided into 
4 groups; the first group served as initial control 
(5 rats) and the other three groups consisting of 
10 rats each. The rats of the first group (initial 
control) were sacrificed on the first day of the 
experiment. The second group served as control 
and received intraperitoneal (IP) administration 
of the vehicle (0.1 ml distilled water /rat/day). 
The third group of the low dose received BRO 
(IP) (2.5mg/kg BW), and the fourth group of the 
high dose received BRO (5 mg/kg BW) for two 
durations i.e. 7 days and 21 days.  Five rats of 
each group were sacrificed 24h after the last 
administration (22 and 36 days old respectively) 
and remaining five rats of each group of each 
duration were maintained for 1 month without 
treatment (52 and 66 days old) to study whether 
or not the effect of BRO were reversible. 
Bodyweight of each mouse during the whole 
study was also recorded. 
Biochemical assay 
Blood samples were collected and serum 
was separated and stored at -20 ºC for 
determining serum level of alkaline phosphatase 
(U/L) by the International Federation of finical 
chemistry method (IFCC) as an indicator 
whether the liver functions have been affected or 
not (Bowers and McComb, 1966). 
Histology of the liver  
At autopsy, the weight of the liver was 
recorded and later converted into relative weight. 
Liver organs were washed with saline to remove 
blood stain and fixed in Bouin’s fixative, 
dehydrated with different grades of alcohol, 
cleared in chloroform, infiltrated with molten 
paraffin wax and embedded in paraffin wax.  
Sections of 5µm thickness were taken and 
stained with haematoxylin and eosin and 
evaluated under the light microscope (Bancroft 
and Gamble, 2008). 
Recovery experiment 
 Five immature rats from each group 
(Control, low dose and a high dose of BRO) of 
each duration (7 and 21 days) were maintained 
without treatment for one month to study the 
reversibility effect of BRO. Rats were sacrificed 
after one month and weights of the body and 
liver were recorded. Blood samples were 
collected and serum was separated and stored 
at -20 ºC for determining serum level of alkaline 
phosphatase (U/L). 
Statistical analysis 
The mean values of each parameter were 
computed considering data from 5 rats per group 
and expressed as mean ± SE. One-way analysis 
of variance (ANOVA) followed by Duncan’s new 
multiple range tests (DMRT) was used to 
determine significant differences among mean 
values. Mean values were judged significantly 
different if P<0.05. 
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RESULTS 
Bodyweight  
There was a significant decrease in the 
bodyweight of immature rats of low and high 
treated groups (2.5 and 5 mg/kg BW) 
respectively when compared to the control 
group. However, there was no significant 
difference in the bodyweight of immature female 
rats following treatment with low and high BRO 
doses one month after cessation of treatment 
compared to the control group (Figures 1 and 2). 
 
 
Fig. 1. Mean body weight of female immature rats of control, low dose, and high dose treated groups following 7 days 
treatment and 1 month after cessation of 7 days treatment.  Bars with same superscript letters are not significantly different, 
whereas those with different superscript letters are significantly (P<0.05) different, as judged by ANOVA following Duncan multiple 
range test. Control:(0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg BW),  High dose: (5mg/kg BW). 
 
 
Fig. 2. Mean body weight of female immature rats of control, low dose, and high dose treated groups following 21 
days treatment and 1 month after cessation of 21 days treatment.  Bars with same superscript letters are not significantly 
different, whereas those with different superscript letters are significantly (P<0.05) different, as judged by ANOVA following Duncan 
multiple range test. Control: (0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg BW),  High dose: (5mg/kg BW). 
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Liver weight  
There was a significant increase in the 
mean relative weight of the liver of immature 
female rats of low and high BRO treated groups 
(2.5 and 5 mg/day BW) respectively compared 
to the control group. There was no significant 
difference in the mean relative weight of the liver 
of low and high BRO treated immature female 
rats one month after cessation of BRO treatment 
when compared to the control group (Figures 3 
and 4). 
 
 
Fig. 3. Mean weight of the liver of female immature rats of control, low dose and high dose treated groups following 7 
days treatment and 1 month after cessation of 7 days treatment.  Bars with same superscript letters are not significantly 
different, whereas those with different superscript letters are significantly (P<0.05) different, as judged by ANOVA following Duncan 
multiple range test. Control: (0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg BW), High dose: (5mg/kg BW). 
 
 
Fig. 4. Mean weight of the liver of female immature rats of control, low dose and high dose treated groups following 
21 days treatment and 1 month after cessation of 21 days treatment.  Bars with same superscript letters are not 
significantly different, whereas those with different superscript letters are significantly (P<0.05) different, as judged by ANOVA 
following Duncan multiple range test. Control: (0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg BW), High dose: (5mg/kg BW). 
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Biochemical assay:   
Serum Alkaline phosphatase level (U/L) 
There was no significant difference in 
the mean of serum alkaline phosphatase level of 
the initial control and the controls of both 
durations. Whereas, there was a significant 
increase in the mean serum alkaline 
phosphatase level of low and high treated 
groups compared to the controls (Table 1). One 
month after cessation of 7 and 21 days 
treatment showed that there was no significant 
difference in the mean serum alkaline 
phosphatase level of both treated groups 
compared to the controls (Table 1). 
 
Table 1. Mean serum alkaline phosphatase levels in immature female rats administered with bromocriptine for 7 and 
21 days and one month after cessation of the treatment. 
 
 
Groups 
Mean serum alkaline phosphatase levels (U/L) ± SE 
7 days of  treatment             
(15-21 days old) 
1 month after 
cessation of 7 days 
treatment (22-52 days 
old) 
21 days of  
treatment               
(15-35 days old) 
1 month after cessation 
of 21 days treatment 
(36-66 days old) 
Initial control                       
(15 days) 
615.18 ± 31.17
a
 - 564.40 ± 20.29
a
 - 
Control 695.2 ± 131.31
a
 316.6 ± 47.42
a
 636.20± 40.20
a
 341.6 ± 29.42
a
 
Low dose 748.20 ± 93.90
b
 298.0 ± 29.98
a
 1091.2 ± 133.38
b
 331.20± 19.52
a
 
High dose 792.40 ± 36.25
b
 292.4 ± 10.0
a
 1220.2 ± 193.46
b
 329.20± 26.95
a
 
ANOVA                           
F-value                             
(df=3,16) 
8.02 
P<0.001 
NS 
4.36 
P<0.05 
NS 
Note: Values with the same superscript letters are not significantly (P<0.05) different whereas those with different 
superscript letters are significantly (P<0.05) different.  df= degree of freedom.   F -values were compared using one 
way ANOVA.  
 
Histological study of the liver 
Sections of the liver of initial control and 
control rats showed normal histological 
architecture. It showed of hexagonal or 
pentagonal lobules with central veins and 
peripheral hepatic triads or tetrads embedded in 
connective tissue.  Hepatocytes are arranged in 
trabeculae running radiantly from the central 
vein and are separated by sinusoids containing 
Kupffer cells.  They are regular and contain a 
large spheroidal nucleus with a distinctly marked 
nucleolus and peripheral chromatin distribution 
(Figure 5).  Histopathological changes in the 
cross-section of the liver of BRO treated groups 
following both durations were noticed. Liver 
sections showed that some hepatocytes were 
enlarged and contained empty vacuole-like 
spaces, degeneration, vacuolation, infiltration in 
the hepatocytes, infiltration of leukocytes and 
hemorrhage were also noted. These changes 
were more in higher doses (Figure 5 and 6). On 
the other hand, liver sections exhibit normal 
appearance one month after cessation of 7 and 
21 days treatment when compared to the 
controls (Figure 6).  
 
Fig. 5. Cross-section of the liver of rats of (A) initial 
control and (B) control showing normal appearance of the 
liver, normal hepatocytes (H), sinusoids (S), normal Kupffer 
cells (arrows), normal central vein (CV); (C) cross-section of 
the liver of immature rats treated with low dose of BRO for 7 
days & (D ) cross-section of the liver of immature rats treated 
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with high dose of BRO for 7 days showing some 
degenerated changes: necrosis of hepatocytes with 
degenerated nucleus (arrows), modest enlarged of 
hepatocytes with vacuolation changes (arrowheads), little 
bubbles of fat inside hepatocytes (asterisk).  400x, H & E.  
Control: (0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg 
bw), High dose: (5mg/kg bw). 
 
 
Fig. 6. Cross-section of the liver of rats of (E) cross-
section of the liver of immature rats treated with low dose of 
BRO for 21 days showing degenerated (arrows) and 
vacuolation of hepatocytes (arrowheads) and an infiltration of 
leukocytes (inf); (F) cross-section of the liver of immature 
rats treated with high dose of BRO for 21days showing high 
degree of degenerated and vacuolation of hepatocytes 
(arrows) beside a hemorrhage (hem). Cross-sections of 
immature rats in (G), one month after cessation of 21 days 
treatment of low dose group, and in (H), one month after 
cessation of 21 days treatment of high dose group, showing 
healthy-looking, more or less like control rats liver sections 
with less degenerated changes. 400x, H & E. 
Control: (0.1ml distilled water/day/rat), Low dose: (2.5 mg/kg 
bw), High dose: (5mg/kg bw).  
 
DISCUSSION 
The present study reveals that the 
treatment of low and high doses of bromocriptine 
either for 7 or 21 days in immature female rats 
caused a significant reduction in the mean body 
weight which attributed to the reduction in food 
intake in immature female rats. Our finding is in 
agreement with some other studies 
demonstrated either on animals (Eiscmann et 
al., 1984; Cincotta and Meier, 1989) or human 
(Meier and Cincotta, 1992) who also reported 
reduction in the bodyweight following 
bromocriptine treatment which might be due to 
its actions as a dopamine agonist which is 
necessary for regulating body’s energy 
expenditure and also its actions on hepatic 
triglycerides (Ingram et al., 2000). The mean 
relative weight of the liver in immature female 
rats has been increased significantly following 
treatment with bromocriptine when compared to 
the control group which might be attributed to 
the increase in the inflammatory cell, infiltration 
of mononuclear cells from the blood vessels and 
haemorrhage in liver tissues which attributed 
with some of the founded histopathological 
changes.   
The liver is the largest organ and one of 
the most important organs in the body. The liver 
regulates the level of most of the biomolecules 
found in the blood and acts with the kidneys to 
clear the blood from drugs and toxic substances. 
The liver metabolizes these products, alters their 
chemical structure, makes them water-soluble, 
and excretes them in bile. Some liver function 
tests such as alkaline phosphatase tests are 
used to determine if the liver has been damaged 
or its function impaired. Elevations of these 
markers for liver injury or disease indicate that 
something is interrupted with the liver (Burtis, 
1999). Literature reviews revealed the 
availability of poor data that deal with the effect 
of bromocriptine on the liver in immature 
mammals. It has been reported that the effects 
of bromocriptine on the liver of women showed 
that small group of hyperprolactinemic patients 
treated with bromocriptine have a transient 
asymptomatic increase in serum alkaline 
phosphatase (Gillam et al., 2006). On the other 
hand, Mahmood et al. (2010) found that 
treatment with bromocriptine in women showed 
no abnormality in the liver function test. 
Whereas, data on the effect of bromocriptine on 
liver function test, for instance, serum alkaline 
phosphatase levels in immature females are not 
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available. Therefore, the present study showed 
for the first time that there was a significant 
increase in the serum level of alkaline 
phosphatase following treatment with low and 
high doses of bromocriptine either following 7 or 
21 days treatment. In accordance with the 
elevation in serum level of alkaline phosphatase 
following bromocriptine treatment, marked 
histological changes were noticed in liver tissues 
in immature female rats which revealed 
degeneration, vacuolation, infiltration in the 
hepatocytes, an infiltration and hemorrhage 
which were more clear in higher dosage either 
following 7 or 21 days of treatment. Our finding 
is in agreement with other studies that showed 
that bromocriptine treatment in humans-caused 
liver injury (Liberato et al., 1992; Livertox, 2013; 
Adejoke et al., 2014). On the other hand, some 
studies on BRO showed that it has no adverse 
effects on the histology of the liver whereas it 
causes significant increase in the biochemical 
parameters of the liver as this elevation was mild 
and still situated within a normal limits of these 
parameters in hyperprolactinemic women 
(Mahmood et al., 2010).  
One of the objectives of the present study 
was to investigate the reversibility effects of 
bromocriptine treatment in immature female rats.  
Rats were examined one month after cessation 
of treatment to find out whether each of the 
parameters studied in the present study was 
restored to normalcy or not. The serum level of 
alkaline phosphatase showed noticeable 
progress. It restored to normalcy in low and high 
dose treated rats though they were normalized 
one month after cessation of treatment. Hence, 
the result of the present study also reveals for 
the first time that treatment with bromocriptine 
(2.5 and 5 mg/kg BW) has side effects on the 
liver in immature female rats through increasing 
the level of alkaline phosphatase in serum 
following treatment with low and high dose of 
bromocriptine either after 7 or 21 days 
treatment. Interestingly, it has been found that 
bromocriptine exerts a reversible effect in the 
liver of immature female rats. This indicates that 
a period of one month was sufficient for the 
recovery of BRO toxic effect which might be 
attributed to the ability of hepatocytes in 
immature female rats to regenerate itself during 
a period of one month.  The present study 
reported that a period of one month was 
sufficient for the recovery of the toxic effect of 
bromocriptine on the liver of immature female 
rats. Hence, the important contribution of the 
present study is, despite the effect of BRO on 
the liver of immature female rats, BRO confirms 
that it has a reversible effect one month after 
cessation of treatment. 
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